ADA and severe combined immunodeficiency: In 2016 the first gene therapy in the EU was approved, GSK’s Strimvelis for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID), and is presently only reimbursed in Italy, whereas ChondroCelect, the first EU approved cell therapy, is still only covered in Spain, Belgium and the Netherlands.